These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 21850283)

  • 21. Denosumab--an emerging treatment for postmenopausal osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2010 Mar; 10(3):467-76. PubMed ID: 20095877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Denosumab. Limited efficacy in fracture prevention, too many adverse effects.
    Prescrire Int; 2011 Jun; 20(117):145-8. PubMed ID: 21678700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.
    Bone HG; Bolognese MA; Yuen CK; Kendler DL; Wang H; Liu Y; San Martin J
    J Clin Endocrinol Metab; 2008 Jun; 93(6):2149-57. PubMed ID: 18381571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role and efficacy of denosumab in the treatment of osteoporosis: an update.
    Charopoulos I; Orme S; Giannoudis PV
    Expert Opin Drug Saf; 2011 Mar; 10(2):205-17. PubMed ID: 21208140
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab.
    Rizzoli R; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Aug; 9(8):591-2. PubMed ID: 20671758
    [No Abstract]   [Full Text] [Related]  

  • 26. Denosumab for the treatment of osteoporosis.
    Iqbal J; Sun L; Zaidi M
    Curr Osteoporos Rep; 2010 Dec; 8(4):163-7. PubMed ID: 20857349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical utility of denosumab for treatment of bone loss in men and women.
    Adler RA; Gill RS
    Clin Interv Aging; 2011; 6():119-24. PubMed ID: 21753866
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.
    Maldonado-Gonzales E; Pietschmann P
    Wien Med Wochenschr; 2010 Sep; 160(17-18):458-63. PubMed ID: 20714812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RANK ligand inhibition with denosumab for the management of osteoporosis.
    Lewiecki EM
    Expert Opin Biol Ther; 2006 Oct; 6(10):1041-50. PubMed ID: 16989586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging treatments for postmenopausal osteoporosis - focus on denosumab.
    Geusens P
    Clin Interv Aging; 2009; 4():241-50. PubMed ID: 19554095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Denosumab: in cancer treatment-induced bone loss.
    Muir VJ; Scott LJ
    BioDrugs; 2010 Dec; 24(6):379-86. PubMed ID: 21043545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial.
    Miller PD; Wagman RB; Peacock M; Lewiecki EM; Bolognese MA; Weinstein RL; Ding B; San Martin J; McClung MR
    J Clin Endocrinol Metab; 2011 Feb; 96(2):394-402. PubMed ID: 21159841
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.
    Anastasilakis AD; Toulis KA; Goulis DG; Polyzos SA; Delaroudis S; Giomisi A; Terpos E
    Horm Metab Res; 2009 Oct; 41(10):721-9. PubMed ID: 19536731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Denosumab--a new option in the treatment of osteoporosis.
    Franek E
    Endokrynol Pol; 2011; 62(1):79-83. PubMed ID: 21365584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD.
    Lewiecki EM; Miller PD; McClung MR; Cohen SB; Bolognese MA; Liu Y; Wang A; Siddhanti S; Fitzpatrick LA;
    J Bone Miner Res; 2007 Dec; 22(12):1832-41. PubMed ID: 17708711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Denosumab for the reduction of bone loss in postmenopausal osteoporosis: a review.
    Bridgeman MB; Pathak R
    Clin Ther; 2011 Nov; 33(11):1547-59. PubMed ID: 22108301
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Denosumab--a new efficient osteoporosis therapy].
    Rejnmark L; Vestergaard P; Mosekilde L
    Ugeskr Laeger; 2011 Jan; 173(5):346-9. PubMed ID: 21276398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Smith J; Fan M; Jun S
    J Clin Oncol; 2008 Oct; 26(30):4875-82. PubMed ID: 18725648
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study.
    Ellis GK; Bone HG; Chlebowski R; Paul D; Spadafora S; Fan M; Kim D
    Breast Cancer Res Treat; 2009 Nov; 118(1):81-7. PubMed ID: 19308727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Denosumab for joints and bones.
    Lewiecki EM
    Curr Rheumatol Rep; 2009 Jul; 11(3):196-201. PubMed ID: 19604464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.